(Q43778531)

26 November 2017

title

The histone deacetylase inhibitor valproic acid enhances equine herpesvirus type 1 (EHV-1)-mediated oncolysis of human glioma cells (English)

1 reference

26 November 2017

M C White

1

1 reference

26 November 2017

A R Frampton

series ordinal

2

1 reference

26 November 2017

publication date

11 January 2013

1 reference

26 November 2017

1 reference

26 November 2017

volume

20

1 reference

26 November 2017

issue

2

1 reference

26 November 2017

page(s)

88-93

1 reference

Glioblastoma multiforme: a perspective on recent findings in human cancer and mouse models

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

Malignant gliomas in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

Malignant glioma: genetics and biology of a grave matter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

Equine herpesvirus type 1-mediated oncolysis of human glioblastoma multiforme cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

The DNA sequence of equine herpesvirus-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

Equine herpesvirus 1 and 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

Potential of equine herpesvirus 1 as a vector for immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

A histone deacetylase inhibitor enhances recombinant adeno-associated virus-mediated gene expression in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

Histone Deacetylase Inhibitors Augment Antitumor Efficacy of Herpes-based Oncolytic Viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

Contribution of gene products encoded within the unique short segment of equine herpesvirus 1 to virulence in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

Therapeutic options for recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

Rapamycin enhances the activity of oncolytic herpes simplex virus against tumor cells that are resistant to virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

Oncolytic viruses and histone deacetylase inhibitors--a multi-pronged strategy to target tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

Intelligent design: combination therapy with oncolytic viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

Histone deacetylase inhibitors suppress the expression of inflammatory and innate immune response genes in human microglia and astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

Valproic acid inhibits angiogenesis in vitro and glioma angiogenesis in vivo in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

The requirements for herpes simplex virus type 1 cell-cell spread via nectin-1 parallel those for virus entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

Role for nectin-1 in herpes simplex virus 1 entry and spread in human retinal pigment epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

Current issues and future directions of oncolytic adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

Location and Orientation of Homologous Sequences in the Genomes of Five Herpesviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

7 January 2021

Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

7 January 2021

Histone deacetylase inhibitors suppress IFNalpha-induced up-regulation of promyelocytic leukemia protein

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

7 January 2021

Infection of peripheral blood mononuclear cells with neuropathogenic equine herpesvirus type-1 strain Ab4 reveals intact interferon-α induction and induces suppression of anti-inflammatory interleukin-10 responses in comparison to other viral strain

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.89

7 January 2021

Identifiers

DOI

10.1038/CGT.2012.89

1 reference

Dimensions Publication ID

26 November 2017

1020153882

0 references

1 reference